Monoclonal antibody · Immune activation, directed at programmed cell death protein 1 (PDCD1) · developed by CytomX Therapeutics
CX-188 is a probody, an anti-PD-1 monoclonal antibody whose antigen-binding site is masked by a peptide linked through a protease-cleavable linker. Tumor-associated proteases in the tumor microenvironment cleave the mask, letting the antibody bind PD-1 and disrupt its inhibitory signaling to restore T-cell activity. It is studied in solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03706274 | Phase 1 | Solid Tumor, Adult | Withdrawn | CTMX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumor, Adult
See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTMX catalysts and pipeline →